Recent publications by Researchers affiliated with the Centre for Tropical Medicine and Global Health
Dose‐Optimization of a Novel Co‐Formulated Triple Combination Antimalarial Therapy: Artemether‐Lumefantrine‐Amodiaquine
Tarning J. et al, (2025), Clinical Pharmacology & Therapeutics
Population genomics and transcriptomics of Plasmodium falciparum in Cambodia and Vietnam uncover key components of the artemisinin resistance genetic background
Nayak S. et al, (2024), Nature Communications, 15
Identification of complex Plasmodium falciparum genetic backgrounds circulating in Africa: a multicountry genomic epidemiology analysis.
Miotto O. et al, (2024), The Lancet. Microbe
Reduced red blood cell deformability in vivax malaria.
Rathnam JTT. et al, (2024), The Journal of infectious diseases
Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.
Schilling WHK. et al, (2024), PLoS medicine, 21
Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)
Wongnak P. et al, (2024), The Lancet Infectious Diseases, 24, 953 - 963
SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART)
Maitland K. et al, (2024), Wellcome Open Research, 8, 484 - 484
A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults.
Hanboonkunupakarn B. et al, (2024), NPJ vaccines, 9
Peeling the onion: how complex is the artemisinin resistance genetic trait of malaria parasites?
Kucharski M. et al, (2024), Trends in Parasitology
Understanding patient and family experiences of critical care in Bangladesh and India: What are the priority actions to promote person-centred care?
Inglis R. et al, (2024), PLOS Glob Public Health, 4
Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)
Jittamala P. et al, (2023), The Journal of Infectious Diseases, 228, 1318 - 1325
The feasibility of novel point-of-care diagnostics for febrile illnesses at health centres in Southeast Asia: a mixed-methods study
Adella FJ. et al, (2023), Transactions of The Royal Society of Tropical Medicine and Hygiene, 117, 788 - 796
Intestinal injury and the gut microbiota in patients with Plasmodium falciparum malaria.
Sriboonvorakul N. et al, (2023), PLoS pathogens, 19
Preventing antimalarial drug resistance with triple artemisinin-based combination therapies
Nguyen TD. et al, (2023), Nature Communications, 14
Determinants of Implementation of a Critical Care Registry in Asia: Lessons From a Qualitative Study.
Tolppa T. et al, (2023), J Med Internet Res, 25
Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)
Schilling WHK. et al, (2023), eLife, 12